<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765256</url>
  </required_header>
  <id_info>
    <org_study_id>823635</org_study_id>
    <nct_id>NCT02765256</nct_id>
  </id_info>
  <brief_title>Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease</brief_title>
  <acronym>Holiday</acronym>
  <official_title>Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crohn's and Colitis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage&#xD;
      and antibiotics with or without an antifungal) in the management of active Crohn's Disease&#xD;
      (CD) that is refractory to conventional, immunosuppressive therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Disease Activity by Harvey Bradshaw Index</measure>
    <time_frame>enrollment visit (baseline) and 15 days</time_frame>
    <description>The primary endpoint will be the change in disease activity, as measured by Harvey-Bradshaw Index (HBI) score, between the enrollment visit and Day 15. All participants who withdraw for any reason prior to day 15 will be considered treatment failures. The HBI is a clinical score where points are given for each category below plus number of liquid bowel movements in previous day. A score of 3 or lower is considered remission. A score of 8 or higher is considered severe disease.&#xD;
General Well Being Very well 0 points Slightly below par 1 point Poor 2 points Very poor 3 points Terrible 4 points&#xD;
Abdominal Pain None 0 points Mild 1 point Moderate 2 points Severe 3 points&#xD;
Abdominal Mass None 0 points Dubious 1 point Definite 2 points Definite and tender 3 points&#xD;
Complications None 0 points Arthralgias +1 point Uveitis +1 point Erythema Nodosum + 1 point Aphthous ulcers +1 point Pyoderma Gangrenosum + 1 point Anal fissure + 1 point New fistula + 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Disease Activity by Fecal Calprotectin (FCP)</measure>
    <time_frame>enrollment visit (baseline) and 15 days</time_frame>
    <description>The second primary outcome measure will be the change in disease activity, as measured by fecal calprotectin, between the enrollment visit and day 15. The fecal calprotectin is a stool test which measures intestinal inflammation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change in High-sensitivity C-reactive Protein (hsCRP)</measure>
    <time_frame>enrollment visit (baseline) and 15 days</time_frame>
    <description>A secondary outcome measure will be the change in high-sensitivity C-reactive protein between the enrollment visit and day 15. The high-sensitivity C-reactive protein is a blood test which measures systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of the Treatment Regimen Based on Medication Side Effects and/or Adverse Events (AEs).</measure>
    <time_frame>105 days</time_frame>
    <description>Number of Medication Side Effects and/or Adverse Events (AEs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>400mg orally once daily (Day 1-14)</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>500mg oral suspension 4 times daily (Day 1-14)</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vancocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neomycin</intervention_name>
    <description>neomycin 1000 mg orally three times daily (Days 1-3)</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Neo-Fradin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>ciprofloxacin 750 mg orally twice daily (Day 4-14)</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cipro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol 3350</intervention_name>
    <description>238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Miralax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promethazine</intervention_name>
    <description>PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Phenergan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole placebo</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is capable of giving informed consent&#xD;
&#xD;
          -  Males or females 18-75 years of age&#xD;
&#xD;
          -  Normal kidney function (defined by normal serum creatinine [male: &lt;1.27 mg/dL; female:&#xD;
             &lt;1.03 mg/dL])&#xD;
&#xD;
          -  Normal aspartate aminotransferase [AST] (&lt;41 U/L), alanine aminotransferase [ALT] (&lt;63&#xD;
             U/L), and alkaline phosphatase (&lt;126 U/L)&#xD;
&#xD;
          -  Active CD defined as HBI ≥ 7&#xD;
&#xD;
          -  CRP &gt; 5 mg/dL or hs-CRP &gt; 10mg/L (or 1mg/dL) or fecal calprotectin (FCP) &gt; - - 350&#xD;
             mcg/g (within one month of enrollment)&#xD;
&#xD;
          -  Have been treated with one of the following therapies** for at least 8 weeks with&#xD;
             primary nonresponse or an initial response, followed by loss of response [LOR]&#xD;
             (self-reported worsening of symptoms for ≥ 7 days): azathioprine, 6-mercaptopurine,&#xD;
             methotrexate, adalimumab, certolizumab, golimumab, infliximab, natalizumab,&#xD;
             vedolizumab, or ustekinumab **These medications must have been administered at&#xD;
             standard, therapeutic dosages.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected stricturing disease producing obstructive symptoms&#xD;
&#xD;
          -  Active Clostridium difficile infection&#xD;
&#xD;
          -  Unwillingness to provide informed consent&#xD;
&#xD;
          -  Allergy or intolerance to the medications used in this study&#xD;
&#xD;
          -  History of kidney disease&#xD;
&#xD;
          -  History of liver disease&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Baseline QTc interval on EKG &gt; 430 in males or &gt; 450 in females&#xD;
&#xD;
          -  Participants who, in the opinion of the investigator, may be non-compliant with study&#xD;
             schedules or procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Albenberg, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James D Lewis, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <results_first_submitted>January 7, 2021</results_first_submitted>
  <results_first_submitted_qc>February 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2021</results_first_posted>
  <disposition_first_submitted>December 1, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>December 1, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 3, 2019</disposition_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Lindsey Albenberg</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Neomycin</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02765256/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluconazole</title>
          <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole: 400mg orally once daily (Day 1-14)&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole placebo: Once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluconazole</title>
          <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole: 400mg orally once daily (Day 1-14)&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole placebo: Once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="26" upper_limit="54"/>
                    <measurement group_id="B2" value="32.5" lower_limit="20" upper_limit="66"/>
                    <measurement group_id="B3" value="39.5" lower_limit="20" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Disease Activity by Harvey Bradshaw Index</title>
        <description>The primary endpoint will be the change in disease activity, as measured by Harvey-Bradshaw Index (HBI) score, between the enrollment visit and Day 15. All participants who withdraw for any reason prior to day 15 will be considered treatment failures. The HBI is a clinical score where points are given for each category below plus number of liquid bowel movements in previous day. A score of 3 or lower is considered remission. A score of 8 or higher is considered severe disease.&#xD;
General Well Being Very well 0 points Slightly below par 1 point Poor 2 points Very poor 3 points Terrible 4 points&#xD;
Abdominal Pain None 0 points Mild 1 point Moderate 2 points Severe 3 points&#xD;
Abdominal Mass None 0 points Dubious 1 point Definite 2 points Definite and tender 3 points&#xD;
Complications None 0 points Arthralgias +1 point Uveitis +1 point Erythema Nodosum + 1 point Aphthous ulcers +1 point Pyoderma Gangrenosum + 1 point Anal fissure + 1 point New fistula + 1</description>
        <time_frame>enrollment visit (baseline) and 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole: 400mg orally once daily (Day 1-14)&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole placebo: Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disease Activity by Harvey Bradshaw Index</title>
          <description>The primary endpoint will be the change in disease activity, as measured by Harvey-Bradshaw Index (HBI) score, between the enrollment visit and Day 15. All participants who withdraw for any reason prior to day 15 will be considered treatment failures. The HBI is a clinical score where points are given for each category below plus number of liquid bowel movements in previous day. A score of 3 or lower is considered remission. A score of 8 or higher is considered severe disease.&#xD;
General Well Being Very well 0 points Slightly below par 1 point Poor 2 points Very poor 3 points Terrible 4 points&#xD;
Abdominal Pain None 0 points Mild 1 point Moderate 2 points Severe 3 points&#xD;
Abdominal Mass None 0 points Dubious 1 point Definite 2 points Definite and tender 3 points&#xD;
Complications None 0 points Arthralgias +1 point Uveitis +1 point Erythema Nodosum + 1 point Aphthous ulcers +1 point Pyoderma Gangrenosum + 1 point Anal fissure + 1 point New fistula + 1</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" lower_limit="-7" upper_limit="0"/>
                    <measurement group_id="O2" value="-3" lower_limit="-8" upper_limit="-2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Disease Activity by Fecal Calprotectin (FCP)</title>
        <description>The second primary outcome measure will be the change in disease activity, as measured by fecal calprotectin, between the enrollment visit and day 15. The fecal calprotectin is a stool test which measures intestinal inflammation.</description>
        <time_frame>enrollment visit (baseline) and 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole: 400mg orally once daily (Day 1-14)&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole placebo: Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disease Activity by Fecal Calprotectin (FCP)</title>
          <description>The second primary outcome measure will be the change in disease activity, as measured by fecal calprotectin, between the enrollment visit and day 15. The fecal calprotectin is a stool test which measures intestinal inflammation.</description>
          <units>mcg/g</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" lower_limit="-116.48" upper_limit="94"/>
                    <measurement group_id="O2" value="-380.5" lower_limit="-1234" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in High-sensitivity C-reactive Protein (hsCRP)</title>
        <description>A secondary outcome measure will be the change in high-sensitivity C-reactive protein between the enrollment visit and day 15. The high-sensitivity C-reactive protein is a blood test which measures systemic inflammation.</description>
        <time_frame>enrollment visit (baseline) and 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole: 400mg orally once daily (Day 1-14)&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole placebo: Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in High-sensitivity C-reactive Protein (hsCRP)</title>
          <description>A secondary outcome measure will be the change in high-sensitivity C-reactive protein between the enrollment visit and day 15. The high-sensitivity C-reactive protein is a blood test which measures systemic inflammation.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="1.1" upper_limit="8.3"/>
                    <measurement group_id="O2" value="-2" lower_limit="-2.9" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of the Treatment Regimen Based on Medication Side Effects and/or Adverse Events (AEs).</title>
        <description>Number of Medication Side Effects and/or Adverse Events (AEs)</description>
        <time_frame>105 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluconazole</title>
            <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole: 400mg orally once daily (Day 1-14)&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole placebo: Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of the Treatment Regimen Based on Medication Side Effects and/or Adverse Events (AEs).</title>
          <description>Number of Medication Side Effects and/or Adverse Events (AEs)</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>105 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluconazole</title>
          <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole: 400mg orally once daily (Day 1-14)&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Vancomycin: 500mg oral suspension 4 times daily (Day 1-14)&#xD;
Neomycin: neomycin 1000 mg orally three times daily (Days 1-3)&#xD;
Ciprofloxacin: ciprofloxacin 750 mg orally twice daily (Day 4-14)&#xD;
Polyethylene Glycol 3350: 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2&#xD;
Promethazine: PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).&#xD;
Fluconazole placebo: Once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Perianal irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Defecation urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment was difficult due to intensive methods with large number of/frequent study visits required. Small sample size is a major limitation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lindsey Albenberg, DO</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>267-426-0139</phone>
      <email>albenbergl@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

